International Reference Pricing: How Countries Set Generic Drug Prices

When you pick up a generic pill at the pharmacy, you might not think about how its price was decided. But behind every low-cost medicine is a complex system governments use to keep prices down-international reference pricing. It’s not magic. It’s math, politics, and sometimes, desperation.

What Is International Reference Pricing?

International reference pricing (IRP) is when a country looks at what other nations charge for the same generic drug and uses that to set its own price. It’s not about what the drug costs to make. It’s about what everyone else is paying. This isn’t new. Italy started it in 1984. By the 2020s, 34 out of 38 high-income countries were using some version of it.

For generic drugs-those that copy brand-name medicines after patents expire-IRP became a go-to tool. Why? Because generics are cheap to produce. Once the patent expires, dozens of manufacturers can make the same pill. That should drive prices down naturally. But in reality, without rules, companies still charge too much. So governments stepped in.

How It Works: Internal vs. External Reference Pricing

There are two main ways IRP is applied to generics: internal and external.

External reference pricing means comparing prices across countries. For example, Germany might look at what France, Spain, Italy, the UK, and the Netherlands charge for a 10mg tablet of atorvastatin. Then it sets its own price based on the average or median of those five.

Internal reference pricing is different. Instead of comparing countries, countries compare drugs. Germany’s system, called AMNOG, groups all interchangeable generics together-say, all 10mg atorvastatin tablets. Then it picks the cheapest one in the group and says: “Everyone else gets reimbursed at that price plus 3%.” If you’re selling a more expensive version, you’re on your own. Patients can still buy it, but they pay the difference.

Most European countries use internal reference pricing for generics. Why? Because it’s simpler. You don’t need to track exchange rates or foreign discounts. You just set one price for the whole group.

Which Countries Are Used as References?

Not every country is fair game. Most Western European nations use the same five: France, Germany, Italy, Spain, and the UK. These are stable markets with transparent pricing. Eastern European countries often pick Austria, Germany, and the Netherlands-countries with higher prices and better data.

Switzerland does something unusual. It doesn’t just pick the average. It takes two-thirds of the international average and adds one-third from Swiss-specific prices. That’s a compromise: it keeps prices low but avoids being dragged down by cheaper neighbors.

The OECD recommends using 5 to 7 countries. More than that? It backfires. A 2020 study by Professor Panos Kanavos found that countries using 10+ reference nations saw only 31% price reduction-but 12% more shortages. Too many references mean too many variables. Prices get messy. Supply chains break.

Why IRP Works for Generics (But Not Always)

The numbers speak for themselves. Countries using IRP for generics pay 25-40% less than those that don’t. In the Netherlands, generic prices are 65-85% lower than the original branded versions. In Germany, the reference system cut administrative costs by 37% because pharmacists and hospitals didn’t have to negotiate each drug individually.

It also pushes substitution. In Spain, 89% of prescriptions for generics are filled with the lowest-priced option-up from 52% in 2010. That’s huge. It means patients get the same medicine at a fraction of the cost.

But here’s the catch: IRP doesn’t work if you ignore reality.

In Greece, during its financial crisis, prices were slashed every quarter. Manufacturers couldn’t keep up. By 2015, 37% of generic drugs were out of stock. Hospitals ran out of blood pressure pills. Patients waited weeks. The system was too aggressive.

Portugal lost 22 generic products in 2019 because prices were set below manufacturing costs. Companies just walked away. No one made them anymore.

And it’s not just about quantity. It’s about quality. Complex generics-like inhalers, injectables, or long-acting tablets-cost more to develop. Some cost nearly as much as brand-name drugs. But IRP treats them the same as simple pills. The FDA saw a 17% drop in new complex generic applications in countries with strict IRP. Why bother investing if you can’t earn back your costs?

The Human Impact: Patients, Pharmacists, and Pharmacies

Patients usually don’t complain about lower prices. A 2021 OECD survey found 78% were happy with generic substitution under IRP. But 34% worried the cheaper version wasn’t as good. That’s not always true-but it’s a real fear.

Pharmacists in Spain and Greece report frequent shortages of the reference-priced product. When the cheapest version runs out, they have to switch to a more expensive one. But patients are often locked into the reference price. So if the pharmacy can’t get the cheapest, they might not be able to dispense the drug at all.

Manufacturers are caught in the middle. Teva’s 2022 report said its European generics revenue dropped 9% due to IRP-even though sales volume rose 15%. Sandoz, on the other hand, said well-designed systems helped them grow market share. The difference? One company adapted. The other fought.

What’s Changing in 2026?

The system isn’t frozen. France launched a new “dynamic reference pricing” system in January 2023. Instead of setting prices once a year, it adjusts them quarterly based on market share. If a cheaper drug takes over, the reference price drops. Early results? 8.2% more savings.

The European Commission started a pilot in April 2023: a shared platform where seven countries pool data on 15 generic drugs. By 2025, they plan to cover 100. This isn’t just about price-it’s about transparency. If everyone sees the same data, it’s harder to hide secret discounts.

IQVIA predicts that by 2027, 65% of European generic prices will be set by reference pricing. But the trend isn’t just about cost. It’s about fairness. The OECD now says IRP systems should be “tiered”-meaning complex generics get different rules than simple ones. That’s a big shift.

The Big Picture: Is IRP Sustainable?

Yes-but only if it evolves.

IRP for generics works because it’s simple, predictable, and effective. It’s not perfect. It causes shortages. It discourages innovation. It punishes small manufacturers. But it’s the best tool we have to keep medicines affordable for millions.

The future isn’t about getting rid of IRP. It’s about making it smarter. Grouping drugs by complexity. Adjusting prices faster. Protecting supply chains. Allowing room for quality.

Countries that treat generics like they’re all the same will keep seeing shortages. Countries that treat them like what they are-medicines with different costs, different risks, different value-will keep their patients covered.

Frequently Asked Questions